Study Stopped
Unforeseen Event - Original PI left the University of Iowa
Ultrasound-based Imaging to Detect Early Changes of Hard and Soft Tissue Around Immediately Placed Implants With or Without Soft Tissue Augmentation
1 other identifier
interventional
31
1 country
1
Brief Summary
Mid-facial recession following immediate implant placement (IIP) in the place of a tooth poses a significant challenge for clinicians to treat. Emerging evidence shows that connective tissue graft (CTG) augmentation may mitigate the remodeling of the buccal bone crest (i.e., bone within the gum that supports the tooth), and lessen the soft tissue recession. A recent systemic review suggested a supplemental CTG grafting to IIP as a standard of care, especially for cases that have a high esthetic risk, specifically with a thin gingival biotype (i.e., thin gum tissue) and a thin buccal bone plate. The alternative option to augment the facial contour is the xenogeneic volume-stable collagen matrix (VCMX), which favors avoiding morbidity but hasn't been thoroughly investigated on IIP. Despite that IIP has attracted considerable scientific interest, the dynamic changes of the bone crest and soft tissue, especially during the early healing stage (\<3 months following IIP), are little known. Recently, an ultrasonography protocol has been validated for its diagnostic value in dental implant research. High-frequency B-mode imaging and color flow and power Doppler are implemented to display the spatial relation of anatomic landmarks of peri-implant tissues and to visualize the flow velocity and blood volume, respectively. It provides a valuable real-time diagnostic tool to evaluate hard and soft tissue remodeling and tissue perfusion changes during the early healing stage around IIP, comparing CTG and VCMX grafting. Hence, the purpose of this three-arm RCT is to compare the clinical efficacy and longitudinal remodeling of hard and soft tissue around IIP among CTG, VCMX, and control (without soft tissue augmentation) group. This will be the first evidence of the longitudinal tissue changes around immediate implant, and the first RCT comparing the clinical efficacy and esthetic outcome of xenogenic soft tissue substitute (i.e., from the non-living bone of another species) to the gold standard approach (CTG) on the immediate implants.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jan 2023
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 8, 2022
CompletedFirst Posted
Study publicly available on registry
April 15, 2022
CompletedStudy Start
First participant enrolled
January 17, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 4, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
March 4, 2024
CompletedResults Posted
Study results publicly available
October 29, 2025
CompletedOctober 29, 2025
August 1, 2025
1.1 years
April 8, 2022
August 28, 2025
October 1, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Percentage of Participants That Had an Implant That Survived 6 Months After Immediate Implant Placement Either With or Without Soft Tissue Grafting
For participants that had immediate implant placement either with or without soft tissue grafting, this outcome is determined via clinical evaluation of the percentage of participants that still had their 1 implant in place after 6 months. Note: Only 1 implant was placed per participant.
6 months after immediate implant placement
Study Arms (3)
Tuberosity Connective Tissue Graft (CTG)
EXPERIMENTALSubjects in this arm will have a tuberosity connective tissue graft at the time of immediate implant placement.
Xenogeneic Volume-Stable Collagen Matrix (VCMX) graft
EXPERIMENTALSubjects in this arm will have Xenogeneic Volume-Stable Collagen Matrix (VCMX) graft at the time of immediate implant placement.
No Soft Tissue Augmentation
NO INTERVENTIONSubjects in this arm will have no soft tissue augmentation at the time of immediate implant placement.
Interventions
Fibro-gide is the VCMX
CTG will be taken from the patient's own mouth
Eligibility Criteria
You may qualify if:
- Age 18-95
- Has a single hopeless tooth in the maxillary esthetic zone (i.e., first premolar to first premolar, tooth #5-tooth #13)
- Adequate oral hygiene (i.e., full-mouth bleeding score (FMBS) and full mouth plaque score (FMPS) of less than 25%)
- Adequate tooth space to support an immediate implant placement (i.e., adequate mesiodistal space of greater than or equal to 6 mm and interocclusal space to support a non-occluding provisionalization).
- Postextraction vertical bone defect of the buccal socket wall was less than or equal to 3mm.
You may not qualify if:
- patients taking long-term (more than 3 months) medications affecting bone metabolism
- generalized untreated periodontitis with greater than of 30% of sites with greater than 5mm pocket depths and bleeding upon probing with a dental probe
- medical contraindications for having a surgical procedure (i.e., ASA Status of III, patient with a severe systemic disease that is not life-threatening; ASA Status of IV, a patient with a severe systemic disease that is a constant threat to life).
- history of radiotherapy in the head and neck region
- heavy smoker (greater than 10 cigarettes per day)
- pregnancy
- gingival recession before extraction in relation to the contralateral tooth.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Iowa College of Dentistry and Dental Clinics
Iowa City, Iowa, 52242, United States
Results Point of Contact
- Title
- Shaoping Zhang
- Organization
- University of Iowa
Study Officials
- PRINCIPAL INVESTIGATOR
Shaoping Zhang, DDS, MS, PhD
University of Iowa
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
April 8, 2022
First Posted
April 15, 2022
Study Start
January 17, 2023
Primary Completion
March 4, 2024
Study Completion
March 4, 2024
Last Updated
October 29, 2025
Results First Posted
October 29, 2025
Record last verified: 2025-08
Data Sharing
- IPD Sharing
- Will not share